Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Redwire Corporation (RDW) Price & Performance

Amylx Pharmaceuticals IncTrade
Redwire CorporationTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Redwire Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Redwire Corporation trades at $13.6 (market cap $3.28B). The key difference: Redwire Corporation is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.

AMLXRDW
Market Cap
$2.53B$3.28B
Sector
HealthTechnology
52-Week High
$24.19$25.90
52-Week Low
$7.82$5.06
Enterprise Value
$2.28B$2.81B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Redwire Corporation

RDW stock trades at $13.59, up 14.88% in the last 24 hours, reflecting strong momentum after Q2 2026 results. The company reported record revenue of $117.1 million and a growing backlog of $542.1 million, though it remains unprofitable with a net income margin of -57.26%. Technical indicators show a bullish trend, with the current price near the consensus target of $17.50, while analyst sentiment is overwhelmingly positive with 80% buy ratings.

The outlook hinges on execution of its space and defense contracts, but persistent losses and negative cash flows from operations pose significant risks. Upside potential exists if margin improvements materialize, yet investors face volatility from earnings misses and high burn rates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Redwire Corporation

Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.

Read more on RDW